(Q36929947)
Statements
Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus (English)
Elizabeth K Hussey
Anita Kapur
Robin O'Connor-Semmes
Wenli Tao
Bryan Rafferty
Charles D James
Robert L Dobbins
30 April 2013
1 reference
1 reference
1 reference